1. Iino Y, Tomioka-Matsutani S, Matsubara A, Nakagawa T, Nonaka M. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease. Auris Nasus Larynx. 2011; 38:456–461.
2. Seo Y, Nonaka M, Tagaya E, Tamaoki J, Yoshihara T. Eosinophilic otitis media is associated with asthma severity and smoking history. ORL J Otorhinolaryngol Relat Spec. 2015; 77:1–9.
3. Nonaka M, Fukumoto A, Ozu C, Mokuno E, Baba S, Pawankar R, Yagi T. IL-5 and eotaxin levels in middle ear effusion and blood from asthmatics with otitis media with effusion. Acta Otolaryngol. 2003; 123:383–387.
4. Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol. 2000; 106:5 Suppl. S201–S205.
5. Corren J, Adinoff AD, Irvin CG. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol. 1992; 89:611–618.
6. Braunstahl GJ, Kleinjan A, Overbeek SE, Prins JB, Hoogsteden HC, Fokkens WJ. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med. 2000; 161:2051–2057.
7. Greiff L, Andersson M, Svensson C, Linden M, Wollmer P, Brattsand R, Persson CG. Effects of orally inhaled budesonide in seasonal allergic rhinitis. Eur Respir J. 1998; 11:1268–1273.
8. Pawankar R. Allergic rhinitis and asthma: are they manifestations of one syndrome? Clin Exp Allergy. 2006; 36:1–4.
9. Braunstahl GJ, Hellings PW. Allergic rhinitis and asthma: the link further unraveled. Curr Opin Pulm Med. 2003; 9:46–51.
10. Tanaka Y, Nonaka M, Yamamura Y, Tagaya E, Pawankar R, Yoshihara T. Improvement of eosinophilic otitis media by optimized asthma treatment. Allergy Asthma Immunol Res. 2013; 5:175–178.
11. Global Initiative for Asthma. GINA report, global strategy for asthma management and prevention - updated 2010. The Global Initiative for Asthma;2010.
12. Iino Y, Nagamine H, Kakizaki K, Komiya T, Katano H, Saruya S, Kodera K. Effectiveness of instillation of triamcinolone acetonide into the middle ear for eosinophilic otitis media associated with bronchial asthma. Ann Allergy Asthma Immunol. 2006; 97:761–766.
13. Ishitoya J, Sakuma Y. Eosinophilic chronic rhinosinusitis and eosinophilic otitis media. Arerugi. 2011; 60:535–545.
14. ten Brinke A, Grootendorst DC, Schmidt JT, De Bruïne FT, van Buchem MA, Sterk PJ, Rabe KF, Bel EH. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol. 2002; 109:621–626.
15. Watson WT, Becker AB, Simons FE. Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. J Allergy Clin Immunol. 1993; 91(1 Pt 1):97–101.
16. Zhu DD, Zhu XW, Jiang XD, Dong Z. Thymic stromal lymphopoietin expression is increased in nasal epithelial cells of patients with mugwort pollen sensitive-seasonal allergic rhinitis. Chin Med J (Engl). 2009; 122:2303–2307.
17. Nagarkar DR, Poposki JA, Tan BK, Comeau MR, Peters AT, Hulse KE, Suh LA, Norton J, Harris KE, Grammer LC, Chandra RK, Conley DB, Kern RC, Schleimer RP, Kato A. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013; 132:593–600.e12.
18. Iinuma T, Okamoto Y, Yamamoto H, Inamine-Sasaki A, Ohki Y, Sakurai T, Funakoshi U, Yonekura S, Sakurai D, Hirahara K, Nakayama T. Interleukin-25 and mucosal T cells in noneosinophilic and eosinophilic chronic rhinosinusitis. Ann Allergy Asthma Immunol. 2015; 114:289–298.
19. Buc M, Dzurilla M, Vrlik M, Bucova M. Immunopathogenesis of bronchial asthma. Arch Immunol Ther Exp (Warsz). 2009; 57:331–344.
20. Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, Watanabe N, Qin FX, Yao Z, Cao W, Liu YJ. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med. 2005; 202:1213–1223.
21. Omori M, Ziegler S. Induction of IL-4 expression in CD4(+) T cells by thymic stromal lymphopoietin. J Immunol. 2007; 178:1396–1404.
22. Simson L, Foster PS. Chemokine and cytokine cooperativity: eosinophil migration in the asthmatic response. Immunol Cell Biol. 2000; 78:415–422.
23. Yao T, Kojima Y, Koyanagi A, Yokoi H, Saito T, Kawano K, Furukawa M, Kusunoki T, Ikeda K. Eotaxin-1, -2, and -3 immunoreactivity and protein concentration in the nasal polyps of eosinophilic chronic rhinosinusitis patients. Laryngoscope. 2009; 119:1053–1059.
24. Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015; 80:372–380.
25. de Marco R, Cazzoletti L, Cerveri I, Corsico A, Bugiani M, Accordini S, Carrozzi L, Dallari R, De Togni A, Marinoni A, Pirina P, Janson C. ISAYA Study Group. Are the asthma guideline goals achieved in daily practice? A population-based study on treatment adequacy and the control of asthma. Int Arch Allergy Immunol. 2005; 138:225–234.
26. Lai CK, De Guia TS, Kim YY, Kuo SH, Mukhopadhyay A, Soriano JB, Trung PL, Zhong NS, Zainudin N, Zainudin BM. Asthma Insights and Reality in Asia-Pacific Steering Committee. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. J Allergy Clin Immunol. 2003; 111:263–268.
27. Hamid Q, Springall DR, Riveros-Moreno V, Chanez P, Howarth P, Redington A, Bousquet J, Godard P, Holgate S, Polak JM. Induction of nitric oxide synthase in asthma. Lancet. 1993; 342:1510–1513.
28. Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med. 2001; 164(8 Pt 1):1376–1381.
29. Warke TJ, Fitch PS, Brown V, Taylor R, Lyons JD, Ennis M, Shields MD. Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax. 2002; 57:383–387.
30. Syk J, Malinovschi A, Johansson G, Undén AL, Andreasson A, Lekander M, Alving K. Anti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized, controlled trial. J Allergy Clin Immunol Pract. 2013; 1:639–648. 648.e1–648.e8.
31. Iino Y, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Kanazawa H, Yoshida N. Clinical efficacy of anti-IgE therapy for eosinophilic otitis media. Otol Neurotol. 2012; 33:1218–1224.
32. Neff BA, Voss SG, Carlson ML, O'Brien EK, Butterfield JH. Treatment of eosinophilic otitis media with pegylated interferon-α 2a and 2b. Laryngoscope. 2017; 127:1208–1216.